Fair and equitable subject selection in concurrent COVID-19 clinical trials
Clinical trials emerged in rapid succession as the COVID-19 pandemic created an unprecedented need for life-saving therapies. Fair and equitable subject selection in clinical trials offering investigational therapies ought to be an urgent moral concern. Subject selection determines the distribution...
| Authors: | ; ; ; ; ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2021
|
| In: |
Journal of medical ethics
Year: 2021, Volume: 47, Issue: 1, Pages: 7-11 |
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 181616397X | ||
| 003 | DE-627 | ||
| 005 | 20230428063545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2020-106590 |2 doi | |
| 035 | |a (DE-627)181616397X | ||
| 035 | |a (DE-599)KXP181616397X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Jansen, O. |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Fair and equitable subject selection in concurrent COVID-19 clinical trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Clinical trials emerged in rapid succession as the COVID-19 pandemic created an unprecedented need for life-saving therapies. Fair and equitable subject selection in clinical trials offering investigational therapies ought to be an urgent moral concern. Subject selection determines the distribution of risks and benefits, and impacts the applicability of the study results for the larger population. While Research Ethics Committees monitor fair subject selection within each trial, no standard oversight exists for subject selection across multiple trials for the same disease. Drawing on the experience of multiple clinical trials at a single academic medical centre in the USA, we posit that concurrent COVID-19 trials are liable to unfair and inequitable subject selection on account of scientific uncertainty, lack of transparency, scarcity and, lastly, structural barriers to equity compounded by implicit bias. To address the critical gap in the current literature and international regulation, we propose new ethical guidelines for research design and conduct that bolsters fair and equitable subject selection. Although the proposed guidelines are tailored to the research design and protocol of concurrent trials in the COVID-19 pandemic, they may have broader relevance to single COVID-19 trials. | ||
| 601 | |a COVID-19 | ||
| 700 | 1 | |a Angelos, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schrantz, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Donington, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Madariaga, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zakrison, L. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 47(2021), 1, Seite 7-11 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:1 |g pages:7-11 |
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2020-106590 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/47/1/7.abstract |x Verlag |z kostenfrei |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4185617917 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 181616397X | ||
| LOK | |0 005 20220908053757 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#1478DEB4BCB0F741FADCC07733039E698A30271E | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||